Screener
Regeneron Pharmaceuticals REGN Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net product sales | $1,642.4 | $1,631.0 | $3,176.9 | $3,046.6 |
| Collaboration revenue | 2,455.0 | 1,860.7 | 4,354.7 | 3,391.9 |
| Other revenue | 193.3 | 183.9 | 364.5 | 265.8 |
| 4,290.7 | 3,675.6 | 7,896.1 | 6,704.3 | |
| Expenses: | ||||
| Research and development | 1,631.6 | 1,421.7 | 3,175.1 | 2,749.1 |
| Acquired in-process research and development | 127.0 | 10.0 | 228.9 | 22.3 |
| Selling, general, and administrative | 662.1 | 634.2 | 1,309.8 | 1,267.2 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's total revenue?
- Regeneron Pharmaceuticals (REGN) reported total revenue of $4.29B in Q2 2026.
- How has Regeneron Pharmaceuticals's total revenue changed year-over-year?
- Regeneron Pharmaceuticals's total revenue increased by 16.7% year-over-year, from $3.68B to $4.29B.
- What is the long-term trend for Regeneron Pharmaceuticals's total revenue?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's total revenue has grown at a -2.8% compound annual growth rate (CAGR), from $16.07B to $14.34B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Regeneron Pharmaceuticals's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude